Shorter hormone therapy for prostate cancer
Dr André-Guy Martin - Centre Hospitalier Universitaire de Québec, Québec City, C...
24 Feb 2020
Micro-ultrasound for detection of clinically significant prostate cancer
Dr Davide Maffei - Humanitas University, Milan, Italy
24 Feb 2020
Revolutionising imaging with PSMA PET in prostate cancer
Dr Bernard Henk-Erik Jansen - VU University Medical Center, Amsterdam, The Nethe...
24 Feb 2020
Follow up from MRI imaging for low-grade prostate cancer
Dr Henk B. Luiting - University of Groningen, Groningen, The Netherlands
24 Feb 2020
Over-diagnosis of low-grade prostate cancer, good or bad?
Prof Hendrik Van Poppel - KU Leuven, Leuven, Belgium
24 Feb 2020
Updates in imaging for oligometastatic disease in urological cancers
Dr Tobias Maurer - University Hospital Hamburg-Eppendorf, Hamburg, Germany
24 Feb 2020
PRIAS: Active surveillance for men with low risk prostate cancer
Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The Nethe...
24 Feb 2020
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic...
Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
19 Feb 2020
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Dr Julie Graff - Oregon Health & Science University, Portland, USA
19 Feb 2020
BCG dosing for bladder cancer: Standard frequency schedule correct
Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany
19 Feb 2020
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA
19 Feb 2020
